Influence of pre-treatment blood pressure levels on antihypertensive drug benefits in diabetics: the roadmap experience

References

• Lewington S, Prospective Studies Collaboration, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–1913.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362(9395):1527–1535.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Algert C, Blood Pressure Lowering Treatment Trialists' Collaboration, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–1419.
   PubMedGoogle Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363(9426):2049–2051.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022–2031.
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Howard SC, Dolan E, et al. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–480.
   PubMed Web of Science ®Google Scholar
• Webb AJ, Fischer U, Mehta Z, et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375(9718):906–915.
   PubMed Web of Science ®Google Scholar
• Hata J, Arima H, Rothwell PM, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325–1334.
   PubMed Web of Science ®Google Scholar
• Stevens SL, Wood S, Koshiaris C, et al. Blood pressure variability and cardiovascular disease: systematic review and meta-analysis. BMJ. 2016;354:i4098
   PubMed Web of Science ®Google Scholar
• Haller H, Ito S, Izzo JL, Jr, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364(10):907–917.
   PubMed Web of Science ®Google Scholar
• Menne J, Ritz E, Ruilope LM, et al. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. J Am Heart Assoc. 2014;3(2):e000810
   PubMed Web of Science ®Google Scholar
• Menne J, Izzo JL, Jr, Ito S, et al. Prevention of microalbuminuria in patients with type 2 diabetes and hypertension. J Hypertens. 2012;30:811–818; discussion 818.
   PubMed Web of Science ®Google Scholar
• Chatzikyrkou C, Menne J. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes. Expert Rev Cardiovasc Ther. 2012;10(9):1087–1092.
   PubMedGoogle Scholar
• Mancia G, Grassi G. Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach. Diabetologia. 2018;61(3):517–525.
   PubMed Web of Science ®Google Scholar
• Passarella P, Kiseleva TA, Valeeva FV, et al. Hypertension Management in Diabetes: 2018. Diabetes Spectr. 2018;31(3):218–224.
   PubMedGoogle Scholar
• Barnett AG, van der Pols JC, Dobson AJ. Regression to the mean: what it is and how to deal with it. Int J Epidemiol. 2004;34(1):215–220.
   PubMed Web of Science ®Google Scholar
• Gill JS, Zezulka AV, Beevers DG, et al. Relation between initial blood pressure and its fall with treatment. Lancet. 1985;325(8428):567–569.
   Google Scholar
• Bhatt DL, Kandzari DE, O'Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393–1401.
   PubMed Web of Science ®Google Scholar
• Pocock SJ, Bakris G, Bhatt DL, et al. Regression to the mean in SYMPLICITY HTN-3: implications for design and reporting of future trials. J Am Coll Cardiol. 2016;68(18):2016–2025.
   PubMed Web of Science ®Google Scholar
• Howard JP, Shun-Shin MJ, Hartley A, et al. Quantifying the 3 biases that lead to unintentional overestimation of the blood pressure-lowering effect of renal denervation. Circ Cardiovasc Qual Outcomes. 2016;9(1):14–22.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Coordinating Committee, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6):1206–1252.
   PubMed Web of Science ®Google Scholar
• German CA, McEvoy JW, Blaha MJ, et al. Implications of the 2017 American College of Cardiology/American Heart Association Hypertension Guideline in a Modern Primary Prevention Multi-Ethnic Prospective Cohort (Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2019;123(7):1076–1082.
   PubMed Web of Science ®Google Scholar
• Hastie CE, Jeemon P, Coleman H, et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertension. Hypertension. 2013;62(4):698–705.
   PubMed Web of Science ®Google Scholar
• Dolan E, O’Brien E. Is it daily, monthly, or yearly blood pressure variability that enhances cardiovascular risk? Curr Cardiol Rep. 2015;17(11):93.
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. ESC/ESH Guidelines for the management of arterial hypertension. Blood Pressure. 2018;27(6):314–340.
   PubMed Web of Science ®Google Scholar
• Griffin SJ, Borch-Johnsen K, Davies MJ, et al. Effect of early inte2nsive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–167.
   PubMed Web of Science ®Google Scholar
• Preiss D, Sattar N, McMurray JJ. A systematic review of event rates in clinical trials in diabetes mellitus: the importance of quantifying baseline cardiovascular disease history and proteinuria and implications for clinical trial design. Am Heart J. 2011;161(1):210–219.e1.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation. 2011;123(24):2799–2810. 9 p following 810.
   PubMed Web of Science ®Google Scholar
• Chatzikyrkou C, Haller H, Menne J. Therapeutic targets in arterial hypertension and diabetes mellitus. Can medical prevention be harmful? Internist. 2012;53(7):882–892.
   PubMed Web of Science ®Google Scholar
• Emdin CA, Rahimi K, Neal B, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–615.
   PubMed Web of Science ®Google Scholar
• Kario K, Okada K, Kato M, et al. 24-Hour blood pressure-lowering effect of an SGLT-2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study. Circulation. 2019;139(18):2089–2097.
   Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116(6):1034–1045.
   PubMed Web of Science ®Google Scholar
• Messerli FH, Bangalore S, Schmieder RE. Wilder’s principle: pre-treatment value determines post-treatment response. Eur Heart J. 2015;36(9):576–579.
   PubMed Web of Science ®Google Scholar